Evangelista Laura, Acampa Wanda, Petretta Mario, Ferro Adele, Ricci Francesca, Luongo Luca, Daniele Stefania, Punzo Giorgio, Cuocolo Alberto
SDN Foundation, Institute of Diagnostic and Nuclear Development, Naples, Italy.
J Nucl Cardiol. 2009 Jan-Feb;16(1):38-44. doi: 10.1007/s12350-008-9004-6. Epub 2009 Jan 20.
We evaluated the incremental prognostic value of viability assessment by nitrate single-photon emission computed tomography (SPECT) in patients with ischemic left ventricular (LV) dysfunction.
One hundred and sixty-four patients with previous myocardial infarction and LV dysfunction (ejection fraction 29% +/- 15%) underwent two Tc-99m sestamibi SPECT studies, under control conditions and after sublingual nitrate administration, for evaluation of myocardial viability. In each patient, viability was defined as the presence of > or = 2 severely dysfunctional segments with preserved tracer uptake (> or = 55% of peak activity). Cardiac death, myocardial infarction, and late (> 2 months) revascularization were considered events. Follow-up was 98% complete at a mean period of 30 +/- 24 months. At baseline SPECT, 119 (73%) patients had evidence of viable myocardium, while 45 (27%) did not. Of these latter patients, 18 (40%) had evidence of viability after nitrate administration. Cardiac events occurred in 58 (35%) patients. Cumulative probability of event-free survival was similar in patients with and without viability at baseline SPECT (log rank 0.3, P = NS), while it was lower in patients with viability at nitrate SPECT compared to those without (log rank 6.3, P < .01). The addition of nitrate SPECT data significantly improved the prognostic power of the model including clinical, functional, angiographic, and baseline SPECT data (P < .01).
In patients with previous myocardial infarction and LV dysfunction, nitrate SPECT imaging provides incremental prognostic information over those obtained from clinical, functional, angiographic variables, and baseline SPECT data.
我们评估了硝酸酯单光子发射计算机断层扫描(SPECT)对缺血性左心室(LV)功能不全患者生存能力评估的增量预后价值。
164例既往有心肌梗死且LV功能不全(射血分数29%±15%)的患者接受了两次锝-99m甲氧基异丁基异腈SPECT研究,一次在对照条件下,另一次在舌下含服硝酸酯后,以评估心肌存活性。在每位患者中,存活性定义为存在≥2个严重功能不全节段且示踪剂摄取保留(≥峰值活性的55%)。心脏死亡、心肌梗死和晚期(>2个月)血运重建被视为事件。随访在平均30±24个月时完成率为98%。在基线SPECT时,119例(73%)患者有存活心肌的证据,而45例(27%)没有。在这些后者患者中,18例(40%)在服用硝酸酯后有存活证据。58例(35%)患者发生了心脏事件。基线SPECT时有无存活性的患者无事件生存的累积概率相似(对数秩检验0.3,P=无显著性差异),而硝酸酯SPECT时有存活性的患者与无存活性的患者相比更低(对数秩检验6.3,P<.01)。添加硝酸酯SPECT数据显著提高了包括临床、功能、血管造影和基线SPECT数据的模型的预后能力(P<.01)。
在既往有心肌梗死和LV功能不全的患者中,硝酸酯SPECT成像比从临床、功能、血管造影变量和基线SPECT数据中获得的信息提供了更多的预后信息。